Conclusions

Recent investigations of mood stabilizers in the treatment of BPD are promising and suggest that these drugs can be useful in clinical practice, particularly for controlling affective instability and impulsive aggression. However, further studies are needed to confirm the initial results and to ascertain whether some novel antipsychotics can be used for their mood-stabilizing effects in patients with BPD.

Future investigations should focus on a list of relevant topics: pilot studies of new drugs; controlled trials of drugs already tested in open case series; comparisons of new anticonvulsant agents with better-known mood stabilizers, such as lithium(Drug information on lithium) or valproate(Drug information on valproate); head-to-head comparisons of novel and traditional antipsychotics to verify which differences in clinical effects and adverse events specifically occur in patients with BPD; maintenance studies to assess persistence of therapeutic effects in longlasting disorders such as BPD; add-on trials of mood stabilizers and novel antipsychotics in samples of patients with BPD who do not respond to firstline therapy with serotonergic antidepressants; and the relationship of clinical subtypes of patients with BPD (eg, affective labile, self-injurious, psychotoform) with response to drug treatment.

Dr Bellino is assistant professor of psychiatry, Dr Paradiso is a resident in psychiatry, and Dr Bogetto is professor of psychiatry and chairman in the department of neuroscience at the University of Turin in Italy.

Drs Bellino, Paradiso, and Bogetto report that they have no conflicts of interest with the subject matter of this article.

Drugs Mentioned in This Article

Carbamazepine (Carbatrol, Tegretol, others)
Clonazepam(Drug information on clonazepam) (Klonopin, Rivotril)
Clozapine (Clozaril)
Divalproex (Epival, Depakote)
Fluoxetine (Prozac)
Lamotrigine(Drug information on lamotrigine) (Lamictal)
Lithium (Eskalith)
Olanzapine (Zyprexa)
Oxcarbazepine(Drug information on oxcarbazepine) (Trileptal)
Phenytoin (Dilantin)
Quetiapine (Seroquel)
Risperidone(Drug information on risperidone) (Risperdal)
Tranylcypromine (Parnate)
Trifluoperazine(Drug information on trifluoperazine) (Stelazine)
Valproate/valproic acid (Depakote, others)

References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
2. Clarkin JF, Yeomans FE, Kernberg OF. Psychotherapy for Borderline Patients. New York: John Wiley & Sons; 1999.
3. Livesley WJ. A practical approach to the treatment of patients with borderline personality disorder. Psychiatr Clin North Am. 2000;23:211-232.
4. American Psychiatric Association. Practice Guidelines for the Treatment of Patients With Borderline Personality Disorder. Washington, DC: American Psychiatric Association; 2001.
5. Vieta E. Mood stabilization in the treatment of bipolar disorder: focus on quetiapine(Drug information on quetiapine). Hum Psychopharmacol. 2005;20:225-236.
6. Sachs GS. Bipolar mood disorder: practical strategies for acute and maintenance phase treatment. J Clin Psychopharmacol. 1996;16:32S-47S.
7. Keck PE Jr, McElroy SL, Richt N, Tohen M. What makes a drug a primary mood stabilizer? Mol Psychiatry. 2002;7(suppl 1):S8-S14.
8. Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry. 2002; 63:146-151.
9. Grof P. "Mood-stabilizers: the archeology of the concept" by M Harris, S Chandran, N Chakraborty and D Healy: a commentary. Bipolar Disord. 2003; 5:453-455.
10. Harris M, Chandran S, Chakraborty N, Healy D. Mood stabilizers: the archeology of the concept. Bipolar Disord. 2003;5:446-452.
11. Keck PE Jr, McElroy SL. Redefining mood stabilization. J Affect Disord. 2003;73:163-169.
12. Mackinnon DF, Pies R. Affective instability as rapid cycling: theoretical and clinical implications for borderline personality and bipolar spectrum disorders. Bipolar Disord. 2006;8:1-14.
13. Zanarini MC, Frankenburg FR, Gunderson JG. Pharmacotherapy of borderline outpatients. Compr Psychiatry. 1988;29:372-378.
14. Gardner DL, Cowdry RW. Pharmacotherapy of borderline personality disorder: a review. Psychopharmacol Bull. 1989;25:515-523.
15. Goldberg SC. Prediction of change in borderline personality disorder. Psychopharmacol Bull. 1989; 25:550-555.
16. Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry. 1999;4:117-128.
17. Links PS, Steiner M, Boiago I, et al. Lithium therapy for borderline patients: preliminary findings. J Clin Psychopharmacol. 1990;4:173-181.
18. Stein DJ. Drug treatment of the personality disorders. Br J Psychiatry. 1992;161:167-184.
19. Ghaemi SN, Ko JY. Oxcarbazepine treatment of bipolar disorder: a review of the literature. Primary Psychiatry. 2002;9:55-59.
20. Gardner DL, Cowdry RW. Positive effects of carbamazepine(Drug information on carbamazepine) on behavioural dyscontrol in borderline personality disorder. Am J Psychiatry. 1986;143:519- 522.
21. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam(Drug information on alprazolam), carbamazepine, trifluoperazine, and tranylcipromine. Arch Gen Psychiatry. 1988;45:111-119.
22. Hori A. Pharmacotherapy for personality disorders. Psychiatry Clin Neurosci. 1998;52:13-19.
23. Mattes J. Comparative effectiveness of carbamazepine and propranolol(Drug information on propranolol) for rage outbursts. J Neuropsychiatry Clin Neurosci. 1990;2:159-164.
24. Kravitz HM, Fawcett J. Carbamazepine in the treatment of affective disorders. Med Sci Res.1987;15: 1-8.
25. Blumer D, Heibronn M, Himmelhoch J. Indications for carbamazepine in mental illness: atypical psychiatric disorder or temporal lobe syndrome? Compr Psychiatry. 1988;29:108-122.
26. Denicoff KD, Meglathery SB, Post RM, Tandeciarz SI. Efficacy of carbamazepine compared with other agents: a clinical practice survey. J Clin Psychiatry. 1994;55:70-76.
27. Emrich H. Studies with oxcarbazepine (Trileptal) in acute mania. Int Clin Psychopharmacol. 1990;5 (suppl 1):83-88.
28. Hellewell JS. Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability. J Affect Disord. 2002;72(suppl 1):S23-34.
29. Hummel B, Walden J, Stampfer R, et al. Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipolar Disord. 2002;4:412-417.
30. Dietrich DE, Kropp S, Emrich HM. Oxcarbazepine in the treatment of affective and schizoaffective disorders. Fortschr Neurol Psychiatr. 2003;71:255- 264.
31. Evins AE. Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J Clin Psychiatry. 2003;64(suppl 8):9-14.
32. Ghaemi SN, Berv DA, Klugman J, et al. Oxcarbazepine treatment of bipolar disorder. J Clin Psychiatry. 2003;64:943-945.
33. Perugi G, Toni C, Frare F, et al. An open case study in Italy of oxcarbazepine, an effective mood stabilizer, in patients with drug resistant/intolerant bipolar I disorders. Poster presented at the XVI Congress of European College of Neuropsychopharmacology; September 20-24, 2003; Prague.
34. Raja M, Azzoni A. Oxcarbazepine versus valproate in mood and schizoaffective disorders. Int J Neuropsychopharm. 2003;6:409-414.
35. Benedetti A, Lattanzi L, Pini S, et al. Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode. J Affect Disord.2004;79:273-277.
36. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord. 2004;6:57-75.
37. Stahl SM. Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels. J Clin Psychiatry. 2004;65:738-739.
38. Yatham LN. Newer anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry. 2004; 65(suppl 10):28-35.
39. Gentry JR, Hill C, Malcolm R. New anticonvulsants: a review of applications for the management of substance abuse disorders. Ann Clin Psychiatry. 2002;14:233-245.
40. Leweke FM, Gerth CW, Koethe D, et al. Oxcarbazepine as an adjunct for schizophrenia. Am J Psychiatry. 2004;161:1130-1131.
41. Bellino S, Paradiso E, Bogetto F. Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry. 2005;66:1111-1115.
42. Polc P. Enhancement of GABAergic inhibition: a mechanism of action of benzodiazepines, phenobarbital(Drug information on phenobarbital), valproate and L-cycloserine in the cat spinal cord. Electroencephalogr Clin Neurophysiol. 1982; 36(suppl):188-198.
43. Wilcox JA. Divalproex sodium(Drug information on divalproex sodium) in the treatment of aggressive behaviour. Ann Clin Psychiatry. 1994;6:17-20.
44. Wilcox JA. Divalproex sodium as a treatment for borderline personality disorder. Ann Clin Psychiatry. 1995;7:33-37.
45. Stein DJ, Simeon D, Frenkel M, et al. An open trial of valproate in borderline personality disorder. J Clin Psychiatry. 1995;56:506-510.
46. Kavoussi RJ, Coccaro EF. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry.1998;59:676-680.
47. Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry. 2001;62:199-203.
48. Hollander E, Swann AC, Coccaro EF, et al. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry. 2005;162:621-624.
49. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2002;63:442-446.
50. Xie X, Hagan RM. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology. 1998;38:119-130.
51. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord. 1998;51:333-343.
52. Green B. Lamotrigine in mood disorders. Curr Med Res Opin. 2003;19:272-277.
53. Preston GA, Marchant BK, Reimherr FW, et al. Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. J Affect Disord. 2004;79:297-303.
54. Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol. 2005;19:287-291.
55. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania: the Depakote Mania Study Group. JAMA. 1994;271:918-924.
56. Jarema M, Sartorius N. Treatment of bipolar disorders with second generation antipsychotic medications. Neuro Endocrinol Lett. 2005;26(suppl 1):5-7.
57. Malhi GS, Berk M, Bourin M, et al. Atypical mood stabilizers: a typical role for atypical antipsychotics. Acta Psychiatr Scand Suppl. 2005;(426):29-38.
58. Muzina DJ, Calabrese JR. Maintenance therapies in bipolar disorder: focus on randomized controlled trials. Aust N Z J Psychiatry. 2005;39:652-661.
59. Vieta E, Goikolea JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord. 2005;7(suppl 4):21-33.
60. Conus P, Berk M, McGorry PD. Pharmacological treatment in the early phase of bipolar disorders: what stage are we at? Aust N Z J Psychiatry. 2006; 40:199-207.
61. Frankenburg FR, Zanarini MC. Clozapine(Drug information on clozapine) treatment of borderline patients: a preliminary study. Compr Psychiatry. 1993;34:402-405.
62. Chengappa KN, Baker RW, Sirri C. The successful use of clozapine in ameliorating severe self-mutilating in a patient with borderline personality disorder. J Personal Disord. 1995;9:76-82.
63. Chengappa KN, Ebeling T, Kang JS, et al. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry. 1999;60:477-484.
64. Benedetti F, Sforzini L, Colombo C, et al. Lowdose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry. 1998;59:103-107.
65. Swinton M. Clozapine in severe borderline personality. J Forensic Psychiatry. 2001;12:580-591.
66. Kouzam HR, Donnelly NJ. Remission of selfmutilation in a patient with borderline personality during risperidone therapy. J Nerv Ment Dis. 1997;185:348-349.
67. Szighethy EM, Schulz SC. Risperidone in comorbid borderline personality disorder and dysthymia. J Clin Psychopharmacol. 1997;17:326-327.
68. Hirose S. Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone. Psych Clin Neurosci. 2001;55:161-162.
69. Rocca P, Marchiaro L, Cocuzza E, Bogetto F. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry. 2002;63:241-244.
70. Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine(Drug information on olanzapine): an updated review of its use in the management of schizophrenia. Drugs. 2001;61:111-161.
71. Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry. 1999;46:1429-1435.
72. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001;62:849-854.
73. Bogenschutz MP, Nurnberg HG. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:104-109.
74. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary randomized trial of fluoxetine(Drug information on fluoxetine), olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J ClinPsychiatry. 2004;65:903-907.
75. Soler J, Pascual JC, Barrachina J, et al. Doubleblind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005;162:1221-1224.
76. Kufferle B, Tauscher J, Asenbaum S, et al. IBZM SPECT imaging of striatal dopamine(Drug information on dopamine)-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol(Drug information on haloperidol). Psychopharmacology. 1997;133:323-328.
77. Hellewell JSE, Cameron Hands D, McKellar J. Seroquel: an effective atypical antipsychotic with no greater EPS than placebo across the full dose range. Schizophr Res. 1998;29:154.
78. Brecher M, Rak IW, Melvin K, et al. The longterm effect of quetiapine (‘Seroquel’) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract. 2000;4:287-291.
79. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transient high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000;57:553- 559.
80. Hilger E, Barnas C, Kasper S. Quetiapine in the treatment of borderline personality disorder. World J Biol Psychiatry. 2003;4:42-44.
81. Adityanjee A, Schulz SC. Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry. 2002;63(suppl 13):32-38.
82. Villeneuve E, Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry. 2005;66:1298-1303.
83. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry. In press.

Evidence-based References

• Green B. Lamotrigine in mood disorders. Curr Med Res Opin. 2003;19:272-277.
• Hollander E, Swann AC, Coccaro EF, et al. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry. 2005;162:621-624. .